{"id":"lasosamide-oral-solution","safety":{"commonSideEffects":[{"rate":"approximately 25-30%","effect":"Dizziness"},{"rate":"approximately 10-15%","effect":"Headache"},{"rate":"approximately 10-15%","effect":"Diplopia (double vision)"},{"rate":"approximately 8-12%","effect":"Nausea"},{"rate":"approximately 5-10%","effect":"Ataxia"},{"rate":"approximately 5-10%","effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lasosamide binds to voltage-gated sodium channels and selectively enhances their slow inactivation phase, which reduces repetitive neuronal firing and prevents seizure propagation. This mechanism differs from traditional sodium channel blockers by specifically targeting the slow inactivation process rather than fast inactivation, potentially offering improved tolerability. The drug is used as an adjunctive antiepileptic agent.","oneSentence":"Lasosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:27.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of partial-onset seizures in epilepsy"}]},"trialDetails":[{"nctId":"NCT02408523","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","startDate":"2015-04","conditions":"Epilepsy","enrollment":242}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1841,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vimpat"],"phase":"phase_3","status":"active","brandName":"Lasosamide Oral Solution","genericName":"Lasosamide Oral Solution","companyName":"UCB BIOSCIENCES, Inc.","companyId":"ucb-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lasosamide enhances slow inactivation of voltage-gated sodium channels, thereby stabilizing neuronal membranes and reducing seizure activity. Used for Adjunctive treatment of partial-onset seizures in epilepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}